A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers
Phase of Trial: Phase I/II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs M 6620 (Primary) ; Topotecan
- Indications Cervical cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 21 Mar 2018 Planned primary completion date changed from 31 May 2019 to 31 May 2024.
- 18 Dec 2017 Results from Phase I portion of this trial published in the Journal of Clinical Oncology
- 07 Nov 2017 Planned End Date changed from 30 Oct 2020 to 30 Oct 2025.